Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on February 10, 2025. The filing addresses Item 5.02 regarding the appointment of a new executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change disclosed is the appointment of Joshua Bleharski, Ph.D., as Chief Financial Officer. Dr. Bleharski is expected to assume the role in early May 2025 following a transition period. He joins the company from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma for nearly 17 years.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. Management commentary is limited to the background of the new CFO and the timeline for his appointment. The company noted that compensation terms for Dr. Bleharski have not yet been finalized and will be disclosed in a subsequent amendment to this report.
Investor Verification Checklist
- Verify the exact start date of Dr. Bleharski's tenure in early May 2025.
- Monitor for the upcoming Form 8-K amendment detailing Dr. Bleharski's compensation package.
- Confirm the departure date of the current Chief Financial Officer, if applicable, to ensure continuity of operations.